Clinical Trial Update: Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding pomalidomide to the standard liposomal daunorubicin/cytarabine chemotherapy in newly diagnosed acute myeloid leukemia with myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Myelodysplasia-related Changes
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• Pomalyst (pomalidomide)
• Vyxeos (CPX-351)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-19